RJSBio is developing “tethered addressed” non-peptide small-molecules for the treatment of cancer and inflammatory conditions.
A cancer drug’s journey to its intended target is a key component to its ultimate success or failure. At RJSBio we define the path of a cancer drug to, and within, a cancer cell using fully-synthetic drug conjugates.
Our modular small-molecule approach leads to efficient uptake of toxic conjugates specifically by cancer cells. Our design minimizes unwanted uptake of these drugs by normal cells, where harmful side effects are manifested.